Boston, Massachusetts 02115

  • Thalassemia Major


The purpose of this study is to find out if using a lower dose of chemotherapy before stem cell transplantation can cure patients of sickle cell anemia or thalassemia while causing fewer severe side effects than conventional high dose chemotherapy with transplantation.

Study summary:

Hemoglobinopathies, such as sickle cell disease and thalassemia major, are genetic diseases associated with significant morbidity and premature death. Allogeneic bone marrow transplantation (BMT) is the only potential cure for severe hemoglobinopathies. Typical regimens have used high doses of chemotherapy or chemo-radiotherapy to ablate recipient hematopoiesis and to prevent graft rejection. The widespread use of this treatment has been limited by toxicity, risk of end-organ damage, and donor availability. This study will use a nonmyeloablative regimen of fludarabine and busulfan to attempt to generate consistent engraftment with donor hematopoietic stem cells in patients with severe hemoglobinopathy. G-CSF mobilization of the donor's peripheral blood white blood cells will precede donor apheresis. A nonmyeloablative conditioning regimen of fludarabine and busulfan will be administered to patients prior to allogeneic peripheral blood stem cell infusions. FK506 and prednisone will be administered for graft versus host disease (GVHD) prophylaxis. Patients will be evaluated for engraftment, donor: host hematopoietic chimerism, toxicity, and hemoglobinopathy.


Inclusion criteria: - All patients must: - Have related donors who are identical at 6 human leukocyte antigens (HLA) loci (A, B and DR) by molecular typing - Have a performance status from 0-2 - Give written informed consent - Patients with sickle cell disease should have 1 or more of the following: - Acute chest syndrome requiring recurrent hospitalization or exchange transfusion - Nonhemorrhagic stroke or central nervous system event lasting longer than 24 hours - Recurrent vaso-occlusive pain (2 episodes or more per year) or recurrent priapism - Sickle nephropathy (moderate or severe proteinuria or a glomerular filtration rate 30-50 percent of normal predicted value) - Bilateral proliferative retinopathy and major visual impairment in at least 1 eye - Osteonecrosis of multiple joints - Patients with thalassemia should have 1 or more of the following: - Transfusion dependence, defined as a transfusion requirement of greater than or equal to 6 units of packed red blood cells over the past 12 months - Iron overload, defined as serum ferritin greater than 500 mcg/L in the absence of infection or biopsy-proven iron overload - Presence of 2 or more alloantibodies against red cell antigens Exclusion criteria: - Pregnancy - Acute hepatitis (transaminases greater than 3 times the normal value) - Cardiac ejection fraction less than 30 percent - Severe renal impairment (glomerular filtration rate less than 30 percent of predicted normal value) - Severe residual functional neurologic impairment (other than hemiplegia alone) - Seropositivity for the human immunodeficiency virus (HIV)



Primary Contact:

Principal Investigator
Catherine J. Wu, MD
Dana Farber Cancer Institute/Harvard Medical School

Backup Contact:


Location Contact:

Boston, Massachusetts 02115
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source:

Date Processed: April 03, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on The form below is not enabled.